Search Within

Breast Medicine Service

Formats
  1. Journal Article (2206)
  2. Meeting Abstract (1680)
  3. Review (83)
  4. Book Section (69)
  5. Editorial (44)
  6. Conference Paper (28)
  7. Guidelines (27)
  8. Correspondence (16)
  9. Miscellaneous (12)
  10. Research Letter (11)
  11. Book Whole (5)
Groups
  1. Department of Medicine (4181)
  2. Solid Tumor Oncology Division (4181)
  3. Survivorship Research (2373)
  4. GSK Faculty (1516)
  5. Population Sciences Research Program (1369)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1144)

More Groups

People
  1. Clifford Hudis (906)
  2. Larry Norton (762)
  3. Mark Robson (684)
  4. Neal Rosen (427)
  5. Andrew Seidman (319)
  6. Kenneth Offit (300)

More People

Years
  1. 2025 (130)
  2. 2024 (195)
  3. 2023 (168)
  4. 2022 (219)
  5. 2021 (236)
  6. 2020 (250)

More Years

Publications
  1. Journal of Clinical Oncology (828)
  2. Cancer Research (481)
  3. Breast Cancer Research and Treatment (170)
  4. Annals of Oncology (159)
  5. Clinical Cancer Research (132)
  6. Cancer (78)

More Publications

Publishers
  1. American Society of Clinical Oncology (880)
  2. American Association for Cancer Research (755)
  3. Springer (332)
  4. Elsevier Inc. (308)
  5. Oxford University Press (282)
  6. Nature Publishing Group (276)

More Publishers

Results (4181)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes in patients (pts) aged ≥ 65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)
    Meeting Abstract

    Kalinsky, K.; Oliveira, M.; Traina, T. A.; Tolaney, S. M.; Loirat, D.; Punie, K.; Hurvitz, S. A.; Lynce, F.; Hamilton, E. P.; Nanda, R.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study
    Meeting Abstract

    Jhaveri, K. L.; Lim, E.; Hamilton, E. P.; Saura, C.; Meniawy, T.; Jeselsohn, R.; Beck, J. T.; Kaufman, P. A.; Sammons, S.; Banda, K.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Racial and ethnic disparities among patients with breast cancer and COVID-19
    Meeting Abstract

    Nagaraj, G.; Accordino, M. K.; French, B.; Kuderer, N. M.; Lyman, G. H.; Stover, D. G.; Blinder, V. S.; Schmidt, A. L.; Shatsky, R. A.; Grover, P.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor + (HR+), HER2-metastatic breast cancer (MBC) not previously treated with a taxane
    Meeting Abstract

    Schwartzberg, L. S.; Bondarenko, I.; Tolaney, S. M.; Seidman, A. D.; O'Shaughnessy, J.; Shparyk, Y. V.; Chung, C. F.; Lu, Y. S.; Chic, N.; Panasci, L. C.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC)
    Meeting Abstract

    Jhaveri, K. L.; Boni, V.; Sohn, J.; Villanueva-Vásquez, R.; Bardia, A.; Schmid, P.; Lim, E.; Patel, J. M.; Perez-Fidalgo, J. A.; Loi, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial
    Meeting Abstract

    Jerusalem, G. H. M.; Park, Y. H.; Yamashita, T.; Hurvitz, S. A.; Modi, S.; Andre, F.; Krop, I. E.; Gonzalez, X.; Hall, P. S.; You, B.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2-) operable breast cancer (BC)
    Meeting Abstract

    Moore, H. M.; Boni, V.; Bellet, M.; De Las Heras, B. B.; Cortés, M. G.; Oakman, C.; Schmid, P.; Trinh, X. B.; Wheatley, D.; Jhaveri, K. L.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Breast cancer screening for carriers of ATM, CHEK2, and PALB2 pathogenic variants: A comparative modeling analysis
    Meeting Abstract

    Lowry, K. P.; Geuzinge, H. A.; Stout, N. K.; Alagoz, O.; Hampton, J. M.; Kerlikowske, K.; Miglioretti, D. L.; Schecter, C.; Sprague, B. L.; Trentham-Dietz, A.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Impact of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy on alpelisib (ALP) benefit in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve
    Meeting Abstract

    Chia, S. K. L.; Ruiz-Borrego, M.; Drullinsky, P.; Juric, D.; Bachelot, T.; Rugo, H. S.; Ciruelos, E. M.; Lerebours, F.; Prat, A.; Akdere, M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer
    Meeting Abstract

    O'Sullivan, C. C. M.; Ballman, K. V.; McCall, L. M.; Zemla, T. J.; Weiss, A.; Mitchell, M.; Blinder, V. S.; Tung, N. M.; Irvin, W. J.; Lee, M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save